636
Results from in vivo expression studies performed with these NF-kappa B p65 mutants revealed the following: 1) I kappa B/MAD-3 completely inhibits NF-kappa B p65 -dependent transcriptional activation mediated through the human immunodeficiency virus type 1 kappa B enhancer in human T lymphocytes , 2) the binding of I kappa B/MAD-3 to NF-kappa B p65 is sufficient to retarget NF-kappa B p65 from the nucleus to the cytoplasm , 3) selective deletion of the functional nuclear localization signal present in the Rel homology domain of NF-kappa B p65 disrupts its ability to engage I kappa B/MAD-3 , and 4) the unique C-terminus of NF-kappa B p65 attenuates its own nuclear localization and contains sequences that are required for I kappa B -mediated inhibition of NF-kappa B p65 DNA binding activity .
 protein: NF-kappa B p65; cell type: human T lymphocytes; protein: I kappa B/MAD-3; protein: NF-kappa B p65; protein: NF-kappa B p65 mutants; protein: C-terminus; protein: NF-kappa B p65; protein: I kappa B; DNA: human immunodeficiency virus type 1 kappa B enhancer; protein: I kappa B/MAD-3; protein: I kappa B/MAD-3; protein: NF-kappa B p65; protein: Rel homology domain; protein: NF-kappa B p65; protein: NF-kappa B p65
Please list all entity words in the text that fit the category.Output format is "type1: word1; type2: word2". 
Option: cell line, protein, RNA, DNA, cell type 
Text: {0} 
Answer:
 protein: NF-kappa B p65; cell type: human T lymphocytes; protein: I kappa B/MAD-3; protein: NF-kappa B p65; protein: NF-kappa B p65 mutants; protein: C-terminus; protein: NF-kappa B p65; protein: I kappa B; DNA: human immunodeficiency virus type 1 kappa B enhancer; protein: I kappa B/MAD-3; protein: I kappa B/MAD-3; protein: NF-kappa B p65; protein: Rel homology domain; protein: NF-kappa B p65; protein: NF-kappa B p65